Recent advances in copper radiopharmaceuticals.

Area of Science:

• Nuclear Medicine
• Radiopharmaceutical Chemistry
• Medical Imaging

Background:

• Copper radioisotopes (e.g., 60Cu, 61Cu, 62Cu, 64Cu, 67Cu) are crucial for developing radiopharmaceuticals.
• Copper-64 (64Cu) is favored for its ideal properties for positron emission tomography (PET) imaging and radiotherapy.
• Advancements in PET scanner availability drive interest in novel copper radiopharmaceuticals for disease diagnosis and treatment.

Purpose of the Study:

• To review unrepresented research aspects of copper chemistry, particularly electrochemistry.
• To explore the use of copper chemistry in designing novel nuclear imaging probes.
• To summarize recent advances in copper radiopharmaceuticals for practical biomedical applications.

Main Methods:

• Literature review focusing on copper chemistry and radiopharmaceutical design.
• Analysis of copper radioisotope properties and their biomedical applications.
• Evaluation of novel imaging probe design strategies.

Main Results:

• Copper radioisotopes offer a range of half-lives and emission properties for diverse nuclear medicine applications.
• Copper-64's low positron energy and mixed-emission profile make it suitable for quantitative PET and targeted radiotherapy.
• Emerging research in copper electrochemistry aids in the development of advanced radiopharmaceutical probes.

Conclusions:

• Copper radiopharmaceuticals, especially those using 64Cu, hold significant promise for improved diagnostic and therapeutic nuclear medicine.
• Further research into copper chemistry, including electrochemistry, is vital for optimizing radiopharmaceutical design and clinical translation.
• This review provides insights into recent progress and future directions in the field of copper radiopharmaceuticals.